Table 1.
Response to treatment with OnabotA in CM patients with and without daily headache.
| Variable | Total Sample (n = 273) | Patients with 15–21 Headache Days/Month (n = 120) | Patients with 22–29 Headache Days/Month (n = 64) | Patients with Daily Headache (n = 89) | p-Value |
|---|---|---|---|---|---|
| 50% response rate (N) | 166 (60.8%) | 82 (68.3%) | 31 (48.4%) | 53 (59.6%) | (p = 0.030) |
| 75% response rate N (%) | 81 (29.7%) | 33 (27.5%) | 20 (31.3%) | 28 (31.5%) | (p = 0.785) |
| Reduction of headache days per month (days) | 11.2 (SD 9.7) | 8.7 (SD: 7.1) | 10.6 (SD: 9.9) | 14.9 (SD: 9.7) | (p < 0.001) |
| Reduction of severe headache days per month (days) | 6.6 (SD: 8.2) | 4.9 (SD: 6.5) | 7.3 (SD: 7.6) | 8.4 (SD: 10.2) | (p = 0.008) |
| Reduction of days of acute medication days use per month (days) | 8.1 (SD: 10.2) | 6.0 (SD: 7.9) | 8.8 (SD: 11.2) | 10.4 (SD: 11.6) | (p = 0.006) |
| Reduction of days of triptan use per month (days) | 2.1 (SD: 7.2) | 2.2 (SD: 7.1) | 3.8 (SD: 7.3) | 0.8 (SD: 7.3) | (p = 0.040) |